Amylin, food intake, and obesity

Obesity Research

Volumn 10, Issue 10, 2002, Pages 1087-1091

  Reda, Tarek K ^a,b,c   Geliebter, Allan ^a   Pi Sunyer, F Xavier ^a  

^a Columbia Univ Coll Phys Surgs ^*  (United States)

^b Nutrition Institute   (Egypt)

^c Nutrition Medical Center   (Egypt)

Author keywords

Amylin; Food intake; Gastric emptying; Satiety; Weight loss

Indexed keywords

AMYLIN; AMYLOID;

CHEMISTRY; EATING; FEMALE; HUMAN; MALE; METABOLISM; OBESITY; PHYSIOLOGY; PSYCHOPHYSIOLOGY; REVIEW; STOMACH EMPTYING;

AMYLOID; EATING; FEMALE; GASTRIC EMPTYING; HUMANS; MALE; OBESITY; SATIETY RESPONSE;

EID: 0036778098     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2002.147     Document Type: Review

References (61)

1. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int. J Obes. Relat Metab Disord. 1998; 22:39-47.
2. Pi-Sunyer FX, Laferrère B, Aronne LJ, Bray GA. Therapeutic controversy: Obesity-a modern-day epidemic. J Clin Endocrinol Metab. 1999;84:3-12.
3. Opie EL. On the relation of chronic interstitial pancreatitis to the islands of Langerhans and to diabetes mellitus. J Exp Med. 1900;5:397-428.
4. Weichselbaum A, Stangl E. Zur kenntnis der feineren veranderungen des pankreas bei diabetes mellitus. Wien Klin Wochenschr. 1901;4:968-72.
5. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA. 1987;84:8628-32.
6. Westermark P, Wernstedt C, O'Brien TD, Hayden DW, Johnson KH. Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am J Pathol. 1987;127:414-7.
7. Ludvik B, Kautzky-Willer A, Prager R, Thomaseth K, Pacini G. Amylin: history and overview. Diabet Med. 1997; 14:89-13.
8. Thompson RG, Peterson J, Gottlieb A, Mullane J. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes. 1997;46:632-6.
9. Young A, Denaro M. Roles of amylin in diabetes and in regulation of nutrient load. Nutrition. 1998;14:524-7.
10. Rushing PA, Hagan MM, Seeley RJ, Lutz TA, Woods SC. Amylin: a novel action in the brain to reduce body weight. Endocrinology. 2000;141:850-3.
11. Kong MF, King P, Macdonald IA, et al. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia. 1997;40:82-8.
12. Butler PC, Chou J, Carter WB, et al. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes. 1990;39:752-6.
13. Mitsukawa T, Takemura J, Asai J, et al. Islet amyloid polypeptide response to glucose, insulin, and somatostatin analogue administration. Diabetes. 1990;39:639-42.
14. O'Brien TD, Westermark P, Johnson KH. Islet amyloid polypeptide and insulin secretion from isolated perfused pancreas of fed, fasted, glucose-treated, and dexamethasone-treated rats. Diabetes. 1991;40:1701-6.
15. Clodi M, Thomaseth K, Pacini G, et al. Distribution and kinetics of amylin in humans. Am J Physiol. 1998;274:E903-E908.
16. Thomaseth K, Kautzky-Willer A, Ludvik B, Prager R, Pacini G. Integrated mathematical model to assess β-cell activity during the oral glucose test. Am J Physiol. 1996;270: E522-31.
17. Ludvik B, Lell B, Hartter E, Schnack C, Prager R. Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes. 1991;40:1615-9.
18. Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA. 1990;37:5036-40.
19. Pittner RA, Albrandt K, Beaumont K, et al. Molecular physiology of amylin. J Cell Biochem. 1994;55S:19-28.
20. Betsholtz C, Christmansson L, Engstrom U, et al. Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species. FEBS Lett. 1989;251;261-4.
21. Jordan K, Murtaugh MP, O'Brien TD, Westermark P, Betsholtz C, Johnson KH. Canine IAPP cDNA sequence provides important clues regarding diabetogenesis and amyloidogenesis in type 2 diabetes. Biochem Biophys Res Commun. 1990;169:502-8.
22. Hartter E, Svoboda T, Ludvik B, et al. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia. 1991;34:52-4.
23. Thomaseth K, Pacini G, Clodi M, et al. Amylin release during oral glucose tolerance test. Diabet Med. 1997;14;S29-S34.
24. Morley JE. Appetite regulation by gut peptides. Annu Rev Nutr. 1990;10:383-96.
25. Geliebter A, Melton PM, Gage D, McCray R, Hashim SA. Gastric balloon to treat obesity: a double-blind study in non-dieting obese subjects. Am J Clin Nutr. 1990;51:584-8.
26. Whitehouse F, Ratner R, Rosenstock J, et al. Pramlintide showed positive effects on body weight in type 1 and type 2 diabetes. Diabetes. 1998;47:A9.
27. Whitehouse F, Kruger DF, Fineman MS, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002;25:724-30.
28. Ratner R, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated patients with type 2 diabetes. Diabetes Technol Ther. 2002;4: 51-61.
29. Morley JE, Flood JF. Amylin decreases food intake in mice. Peptides. 1991;12:865-9.
30. Morley JE, Flood JF, Horowitz M, Morley PM, Walter MJ. Modulation of food intake by peripherally administered amylin. Am J Physiol. 1994;267:R178-84.
31. Devine E, Young AA. Weight gain in male and female mice with amylin gene knockout. Diabetes 1998;47:A317.
32. Rushing PA, Hagan MM, Seeley RJ, et al. Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology. 2001;142:5035.
33. Riediger T, Schmid HA, Lutz T, Simon E. Amylin potently activates AP neurons possibly via formation of the excitatory second messenger cGMP. Am J Physiol Regul Integr Comp Physiol. 2001;281:R1833-43.
34. Chance WT, Balasubramaniam A, Thomas I, Fischer JE. Amylin increases transport of tyrosine and tryptophan into the brain. Brain Res. 1992;593:20-4.
35. Leibowitz SF, Shor-Posner G. Hypothalamic monoamine systems for control of food intake: analysis of meal patterns and macronutrient selection. In: Carube MO, Blundell JE, eds. Psychopharmacology of Eating Disorders: Theoretical and Clinical Advances. New York: Raven Press; 1986, p. 29.
36. Mollet A, Lutz TA, Meier S, Riediger T, Rushing PA, Scharrer E. Histamine H1 receptors mediate the anorectic action of the pancreatic hormone amylin. Am J Physiol Regul Integr Comp Physiol. 2001;281:R1442-8.
37. Lutz TA, Tschudy S, Mollet A, Geary N, Scharrer E. Dopamine D(2) receptors mediate amylin's acute satiety effect. Am J Physiol Regul Integr Comp Physiol. 2001;280: R1697-703.
38. Morris MJ, Nguyen T. Does neuropeptide Y contribute to the anorectic action of amylin? Peptides. 2001;22:541-6.
39. Lutz TA, Pieber TR, Walzer B, Del Prete E, Scharrer E. Different influence of CGRP (8-37), an amylin and CGRP antagonist, on the anorectic effects of cholecystokinin and bombesin in diabetic and normal rats. Peptides. 1997;18: 643-9.
40. Westermark P, Wernstedt C, Wilander E, Sletten K. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun. 1986;140:827-31.
41. Zaidi M, Brain SD, Tippins JR, et al. Structure-activity relationship of human calcitonin-gene-related peptide. Biochem J. 1990;269:775-80.
42. Bhavsar S, Watkins J, Rink T. Synergistic effect of amylin and cholecystokinin octapeptide on food intake in mice. Physiol Behav. 1998;64:557-61.
43. Morley JE, Flood JF. Effect of competitive antagonism of NO synthetase on weight and food intake in obese and diabetic mice. Am J Physiol. 1994;35:R164-8.
44. Morley JE, Flood JF, Farr SA, Perry HJ, III, Kaiser FE, Morley PM. Effects of amylin on appetite regulation and memory. Can J Physiol Pharmacol. 1995;73:1042-6.
45. Morley JE, Suarez MD, Mattamal M, Flood JF. Amylin and food intake in mice: effects on motivation to eat and mechanism of action. Pharmacol Biochem Behav. 1997;56:123-9.
46. Morley JE. Neuropeptide regulation of appetite and weight. Endocr Rev. 1987;8:256-87.
47. Young AA, Gedulin BR, Rink TJ. Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism. 1996;45: 1-3.
48. Horowitz M, Dent J. Disordered gastric emptying: mechanical basis, assessment and treatment. Baillieres Clin Gastroenterol. 1991;5:371-407.
49. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia. 1993;36:857-62.
50. Torsdottir I, Alpsten M, Holm G, Sandberg AS, Tolli J. A small dose of soluble alginate-fiber affects postprandial glycemia and gastric emptying in humans with diabetes. J Nutr. 1991;121:795-9.
51. Bhogal R, Smith DM, Bloom SR. Investigation and characterization of binding sites for islet amyloid polypeptide in rat membranes. Endocrinology. 1992;130:906-13.
52. Rogers RC, McTigue DM, Hermann GE. Vagal control of digestion: modulation by central neural and peripheral endocrine factors. Neurosci Biobehav Rev. 1996;201:57-66.
53. Christopoulos G, Paxinos G, Huang XF, Beaumont K, Toga AW, Sexton PM. Comparative distribution of receptors for amylin and the related peptides calcitonin gene related peptide and calcitonin in rat and monkey brain. Can J Physiol Pharmacol. 1995;73:1037-41.
54. Jodka C, Green D, Young A, Gedulin B. Amylin modulations of gastric emptying in rats depends upon intact vagus nerve. Diabetes. 1996;45(Suppl 1):235A.
55. Edwards GL, Gedulin B, Jodka C, et al. Area postrem (AP)-lesions block the regulation of gastric emptying by amylin. Neurogastroenterol Motil. 1998;10:26.
56. Young AA, Gedulin B, Vine W, Percy A, Rink TJ. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia. 1995;38: 642-8.
57. Nowak TV, Roza AM, Weisbruch JP, Brosnan MR. Accelerated gastric emptying in diabetic rodents: effect of insulin treatment and pancreas transplantation. J Lab Clin Med. 1994; 123:110-6.
58. Gedulin B, Jodka C, Lawler R, Young A. Effect of amylin blockade on gastric emptying in normal HSD and LA/N corpulent rats. The Endocrine Society, Program and Abstracts, 79th Annual Meeting, June 11-14, Minneapolis, MN. Endocrine Society; 1997, p. 194 (abstr P1-240).
59. Phillips WT, Schwartz JG, McMahan CA. Rapid gastric emptying in patients with early non-insulin-dependent diabetes mellitus. N Engl J Med. 1991;324:130-1.
60. Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol Gastrointest Liver Physiol. 2000;278:G946-51.
61. Kolterman OG, Gottlieb A, Moyses C, Colburn W. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care. 1995;18:1179-82.